Phase 2 RCT | Immediate surgery vs. short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer.

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial – The Lancet Gastroenterology & Hepatology

News Release: Chemotherapy before surgery can improve survival rates in pancreatic cancer patients – University of Liverpool

Commentary on Twitter

New research – Ghaneh et al – Immediate surgery vs short-course neoadjuvant gemcitabine + capecitabine, FOLFIRINOX, or chemoradiotherapy in patients w/ borderline resectable #pancreaticcancer (ESPAC5): a randomised phase 2 trialhttps://t.co/9S1hupyKjg#gitwitter #onctwitter pic.twitter.com/g2jQUAhUSJ

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 14, 2022